In October 2015, letters were sent to healthcare professionals to provide safety information for the anticancer medicines crizotinib and vemurafenib
A letter regarding crizotinib has been sent to inform about the risk of cardiac failure.
A letter regarding vemurafenib has been sent to inform about the risk of potentiation of radiation toxicity.
Article citation: Drug Safety Update Vol 9 issue 4, November 2015: 3.
Don’t include personal or financial information like your National Insurance number or credit card details.